Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between ...

The results showed that the metastases had significantly lower levels of LAMP2A compared to the primary tumors. Similar patterns ... underlying causes of cancer cell spread.

In addition, there was heavy IgG4 positive plasma cell infiltration associated with storiform fibrosis in the same lesion, probably pointing to a link between ENST-RDD and IgG4-related disorders.

On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in ...

On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in ...

2. The FDA has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors who will not benefit from surgical resection.

If you just found out that you or your child has a germ cell tumor, you may have a lot of questions about what it means and what comes next. There are many kinds of germ cell tumors, and only some ...

Drug Discovery Lab, Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong SAR 999077, People’s Republic of China Department of Chemistry, National University of ...

Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral CSF1R inhibitor vimseltinib, newly branded Romvimza, could take significant ...

TGCT is a rare, non-malignant tumor that develops inside or near joints. TGCT is caused by dysregulation of the CSF1 gene leading to overproduction of CSF1. TGCT is also known as giant cell tumor ...